Company

NUTSHELL Therapeutics

Shanghai-based biotech developing allosteric drugs with its AlloStar discovery platform and AlloMatrix protein database.

About

Established in 2013 and based in Shanghai, China, NUTSHELL Therapeutics Inc. researches and develops allosteric drugs, with a portfolio of nearly 20 internal programs in oncology, CNS, autoimmune and metabolic diseases. In September 2026 it raised a Series C1 round co-led by Trustar Capital and Decheng Capital, with participation from Fortune Capital and Guolian Group. The new funding will go toward its AI and physical computing platform and core pipelines.

4Funding rounds

12Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in